Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 5 (2008), Issue 6 (June)

1. Media influence on Herceptin subsidization in Australia: application of the rule of rescue?
   J R Soc Med, 101(6): 305-12. [Abstract] [Full-text]
2. Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer.
   Oncologist, 13(5): 515-25. [Abstract] [Full-text]
3. Trastuzumab-induced cardiomyopathy.
   J Card Fail, 14(5): 437-44. [Abstract] [Full-text]
4. Effects of ErbB2 signaling on the response of vestibular schwannoma cells to gamma-irradiation.
   Laryngoscope, 118(6): 1023-30. [Abstract] [Full-text]
5. Neuregulins and cancer.
   Clin Cancer Res, 14(11): 3237-41. [Abstract] [Full-text]
6. Extended survival in women with brain metastases from HER2 overexpressing breast cancer.
   Am J Clin Oncol, 31(3): 250-4. [Abstract] [Full-text]
7. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients.
   J Transl Med, 6: 25. [Abstract] [Full-text]
8. Antibody-Based Therapy for Solid Tumors.
   Cancer J, 14(3): 178-183. [Abstract] [Full-text]
9. Herceptin-platinum(II) binding complexes: novel cancer-cell-specific agents.
   ChemMedChem, 3(6): 954-62. [Abstract] [Full-text]
10. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment.
    Breast Cancer. [Abstract] [Full-text]
11. Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques.
    J Histochem Cytochem, 56(7): 667-75. [Abstract] [Full-text]
12. Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging.
    Clin Cancer Res, 14(12): 3840-9. [Abstract] [Full-text]
13. Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu.
    J Immunother, 31(6): 537-44. [Abstract] [Full-text]
14. Synthesis and evaluation of near-infrared (NIR) dye-herceptin conjugates as photoacoustic computed tomography (PCT) probes for HER2 expression in breast cancer.
    Bioconjug Chem, 19(6): 1186-93. [Abstract] [Full-text]
15. Defining prognosis for women with breast cancer and CNS metastases by HER2 status.
    Ann Oncol, 19(7): 1242-8. [Abstract] [Full-text]
16. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium.
    Health Policy, 87(2): 146-59. [Abstract] [Full-text]
17. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
    Oncologist, 13(6): 725-32. [Abstract] [Full-text]
18. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Oncologist, 13(6): 620-30. [Abstract] [Full-text]

© 2004-2010 Herceptin Research Today. All Rights Reserved.